Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5731 AL 5745

Current therapeutic strategy in Alzheimer's disease

Singh S, Kushwah AS, Singh R, Farswan M, Kaur R.

Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1651-64.

Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation

Lindsley CW.

ACS Chem Neurosci. 2012 Nov 21;3(11):804-5. doi: 10.1021/cn300190f.

Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease

Lin LF, Liao MJ, Xue XY, Zhang W, Yan L, Cai L, Zhou XW, Zhou X, Luo HM.

Neurosci Bull. 2013 Feb;29(1):111-20. doi: 10.1007/s12264-012-1287-6. Epub 2012 Nov 21.

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model

Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.

Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22.

Life orientation in Finnish family caregivers' of persons with Alzheimer's disease: a diary study

Välimäki T, Vehviläinen-Julkunen K, Pietilä AM, Koivisto A.

Nurs Health Sci. 2012 Dec;14(4):480-7. doi: 10.1111/j.1442-2018.2012.00721.x.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124.

Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors

Bolea I, Gella A, Unzeta M.

J Neural Transm (Vienna). 2013 Jun;120(6):893-902. doi: 10.1007/s00702-012-0948-y. Epub 2012 Dec 13.

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LM, Sekler I, Pandolfi A, Sensi SL.

Cell Death Dis. 2012 Dec 20;3(12):e448. doi: 10.1038/cddis.2012.189.

[Tacrine and its derivatives in the therapy of Alzheimers disease]

Korábečný J, Spilovská K, Benek O, Musílek K, Soukup O, Kuča K.

Ceska Slov Farm. 2012 Oct;61(5):210-21.

Curcuminoids and resveratrol as anti-Alzheimer agents

Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY.

Taiwan J Obstet Gynecol. 2012 Dec;51(4):515-25. doi: 10.1016/j.tjog.2012.09.005.

Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways

Silva T, Teixeira J, Remião F, Borges F.

Angew Chem Int Ed Engl. 2013 Jan 21;52(4):1110-21. doi: 10.1002/anie.201204964. Epub 2012 Dec 20.

Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease

Christensen DD.

Postgrad Med. 2012 Nov;124(6):110-6. doi: 10.3810/pgm.2012.11.2589.

Review of drugs for Alzheimer's disease

Sun X, Jin L, Ling P.

Drug Discov Ther. 2012 Dec;6(6):285-90.

[Progress of researches on mechanisms of acupuncture intervention of Alzheimer's disease]

Zhu J, Guo HD, Shao SJ.

Zhen Ci Yan Jiu. 2012 Oct;37(5):422-7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias